Inhalation Sciences Sweden AB (ISAB) has secured two significant orders from a recurring global pharmaceutical customer, totaling EUR 55,250, reinforcing the company's position in the preclinical inhalation research market. The orders demonstrate continued confidence in ISAB's patented PreciseInhale® platform and mark a strategic expansion of the partnership.
Expanding Partnership Drives Revenue Growth
The most recent order, announced July 1, 2025, comprises a EUR 14,250 (158,600 SEK) service agreement covering continued technical support for the customer's existing PreciseInhale® installations. This follows an earlier EUR 41,000 order received in April 2025 for additional instruments and complementary equipment for advanced inhalation research.
The customer, identified as a leading European-headquartered player in inhaled pharmaceuticals, has previously invested in several of ISAB's advanced research instruments. The company has now expanded its collaboration by signing additional service agreements, with more service agreements currently underway.
Technology Validation and Market Position
"The fact that a global pharmaceutical player with several of our instruments chooses to further deepen the collaboration through a new service agreement is a strong confirmation of the long-term value and reliability of our technologies," said Manoush Masarrat, CEO of Inhalation Sciences. "Our ability to provide high-quality technical support is an important part of our customer promise, and we look forward to continuing to strengthen these relationships."
The PreciseInhale® platform is designed for preclinical inhalation research, delivering high reproducibility and precision in pharmaceutical development studies. The technology addresses the growing demand for advanced solutions in inhalation research, a critical area for respiratory drug development.
Strategic Revenue Model
These orders align with ISAB's strategy to build recurring revenue streams and support partners throughout the inhalation research lifecycle. The combination of equipment sales and ongoing service agreements creates a sustainable business model that extends beyond initial instrument purchases.
"The fact that a global player once again chooses to invest in our technology is a strong validation of the quality and precision our systems deliver," Masarrat noted regarding the April order. "We see this as a confirmation of our long-term collaboration and the strategic importance of our products in inhalation research."
The repeat business from this major pharmaceutical customer reinforces ISAB's position as a leading provider of preclinical inhalation research technology and confirms the growing demand for specialized solutions in this therapeutic area.
